A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Pharmaceutics"
DOI: 10.1016/j.ijpharm.2018.06.017
Abstract: Graphical abstract Figure. No caption available. ABSTRACT Non‐cystic fibrosis bronchiectasis (NCFB) characterized by permanent bronchial dilatation and recurrent infections has been clinically managed by long‐term intermittent inhaled antibiotic therapy among other treatments. Herein we investigated… read more here.
Keywords: cip nanoplex; mucus permeability; antibacterial efficacy; cip ... See more keywords